ReviewNature reviews. Clinical oncology2016
Translating neoadjuvant therapy into survival benefits: one size does not fit all.
Review in Nature reviews. Clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies.Cancer medicine · 2017Pooled it
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.The New England journal of medicine · 2017Trial
- Pretreatment dual-energy CT versus diffusion-weighted imaging for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer.BMC medical imaging · 2026Article
- Biomechanical parameters quantified by MR elastography for predicting response to neoadjuvant chemotherapy and disease-free survival in breast cancer: a prospective longitudinal study.Breast cancer research : BCR · 2025Article
- Ferroptotic Neutrophils Induce Immunosuppression and Chemoresistance in Breast Cancer.Cancer research · 2025Article
- Injectable supramolecular hydrogel co-loading abemaciclib/NLG919 for neoadjuvant immunotherapy of triple-negative breast cancer.Nature communications · 2025Article
- Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy.Frontiers in oncology · 2025Article
- Dkk1 as a Prognostic Marker for Neoadjuvant Chemotherapy Response in Breast Cancer Patients.Cancers · 2024Article
- Correlation of Histopathological and Radiological Response Patterns and Their Prognostic Implications in Breast Cancer After Neoadjuvant Chemotherapy.Breast cancer (Dove Medical Press) · 2024Article
- Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy.Discover oncology · 2023Article
- Predicting Pathological Complete Response in Breast Cancer After Two Cycles of Neoadjuvant Chemotherapy by Tumor Reduction Rate: A Retrospective Case-Control Study.Journal of breast cancer · 2023Article
- CD8+ T cell-Dependent Remodeling of the Tumor Microenvironment Overcomes Chemoresistance.Cancer immunology research · 2023Article
- Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay.Journal of breast cancer · 2022Article
- Review
- Therapeutic Strategies for Resectable Stage-IIIA N2 Non-Small Cell Lung Cancer Patients: A Network Meta-Analysis.Clinical Medicine Insights. Oncology · 2022Article
- The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers.NPJ breast cancer · 2021Article
- Prognostic value of using glucosylceramide synthase and cytochrome P450 family 1 subfamily A1 expression levels for patients with triple-negative breast cancer following neoadjuvant chemotherapy.Experimental and therapeutic medicine · 2021Article
- Obesity and high neutrophil-to-lymphocyte ratio are prognostic factors in non-metastatic breast cancer patients.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021Article
- Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.Annals of surgical oncology · 2020Article
- Early response and pathological complete remission in Breast Cancer with different molecular subtypes: a retrospective single center analysis.Journal of Cancer · 2020Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
Neoadjuvant therapy has been established as an effective therapeutic approach for patients with locally advanced breast cancer. Similar outcomes between neoadjuvant and adjuvant chemotherapy have been demonstrated in several trials. Nevertheless, neoadjuvant therapy has some advantages over adjuvant therapy, including tumour downstaging, in vivo assessment of therapeutic efficacy, reduced treatment durations, and the need to enrol fewer patients for clinical trials to reach their preplanned objectives. The number of neoadjuvant trials in patients with breast cancer has increased substantially in the past 5 years, particularly in the context of HER2-positive disease. Substantial improvements in the pathological complete response rate to anti-HER2 therapy, a proposed surrogate end point for long-term clinical benefit, have been observed with neoadjuvant dual-agent HER2 blockade. Thus, it was hypothesized that this approach would provide additional survival benefits over standard-of-care therapy with the anti-HER2 antibody trastuzumab in the adjuvant setting. Emerging data, however, are calling this notion into question. We discuss potential reasons why results of neoadjuvant trials of targeted therapies have not been mirrored in the adjuvant setting, and other than inherent differences in clinical-trial designs and statistical power, we consider how the biology of the disease, patient characteristics, and drug administration and schedule might influence the results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.